GlassScriptPhysician profile
David Scott Schnapp
NPI 1609970854
$4,447.46
in general payments reported to CMS, 2019-2025
43 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $144 · 2021: $824 · 2022: $704 · 2023: $1,042 · 2024: $776 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.12 |
| Education | $103.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $446.93 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $442.41 | 2023-2025 | Prolaris |
| Janssen Biotech, INC. | $335.03 | 2019-2024 | Erleada |
| Astellas Pharma US INC | $322.02 | 2019-2023 | Myrbetriq |
| Teleflex LLC | $321.06 | 2021-2025 | Urolift, Barrigel |
| Abbvie INC. | $317.15 | 2020-2025 | Botox |
| Sumitomo Pharma America, INC. | $213.09 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $195.11 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $157.59 | 2024-2025 | Adstiladrin |
| Accord Healthcare, INC. | $157.02 | 2023-2024 | |
| Neotract INC. | $154.83 | 2019-2020 | |
| Urovant Sciences INC | $121.97 | 2021-2022 | |
| Urogen Pharma, INC. | $100.49 | 2021-2024 | Jelmyto |
| Pfizer INC. | $95.77 | 2019-2023 | |
| Boston Scientific Corporation | $84.89 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schnapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.